Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
McKinsey
Medtronic
Boehringer Ingelheim
Johnson and Johnson

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,276,250

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,276,250
Title:Sustained release formulations of oxymorphone
Abstract:Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
Inventor(s): Baichwal; Anand R. (Wappingers Falls, NY), Kao; Huai-Hung (Syosset, NY), McCall; Troy W. (Germantown, TN)
Assignee: Penwest Pharmaceuticals Company (Danbury, CT)
Application Number:10/189,932
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,276,250
Patent Claim Types:
see list of patent claims
Formulation; Compound; Delivery; Use; Dosage form;

Drugs Protected by US Patent 7,276,250

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-001 Jun 22, 2006 DISCN No No   Start Trial   Start Trial Y RELIEF OF MODERATE TO SEVERE PAIN   Start Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-005 Feb 29, 2008 DISCN No No   Start Trial   Start Trial Y RELIEF OF MODERATE TO SEVERE PAIN   Start Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-002 Jun 22, 2006 DISCN No No   Start Trial   Start Trial Y RELIEF OF MODERATE TO SEVERE PAIN   Start Trial
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-006 Feb 29, 2008 DISCN No No   Start Trial   Start Trial Y RELIEF OF MODERATE TO SEVERE PAIN   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Johnson and Johnson
Express Scripts
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.